Mission Statement, Vision, & Core Values of vTv Therapeutics Inc. (VTVT)

Ever wonder what drives a biopharmaceutical company like vTv Therapeutics (VTVT)?

Understanding a company's core principles can offer valuable insight into its operations and long-term goals. What exactly is the mission, vision, and what are the core values of vTv Therapeutics, a company focused on developing oral, small molecule drug candidates and led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes?

Delving into these guiding statements can reveal the heart of VTVT, showcasing its dedication to advancing treatments for challenging diseases.

vTv Therapeutics Inc. (VTVT) An Overview of

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered treatments for metabolic diseases. While specific, up-to-the-minute sales figures for April 2025 are unavailable, the company's value is based on its research and development pipeline. As a clinical-stage company, vTv Therapeutics' value is heavily influenced by the progress and potential of its drug candidates rather than current product sales. One of their primary focuses has been on developing treatments that can offer solutions where there are unmet medical needs.

Given the nature of clinical-stage biopharmaceutical companies, financial performance is typically characterized by research and development expenses, clinical trial costs, and administrative overhead. Revenue, if any, may come from collaborative agreements, licensing deals, or milestone payments. For instance, in 2024, vTv Therapeutics reported financials that reflect these characteristics. On March 14, 2024, vTv Therapeutics announced a $4.4 million registered direct offering. The offering involved the sale of 11,000,000 shares of common stock at a purchase price of $0.40 per share. Additionally, investors received warrants to purchase up to 11,000,000 shares of common stock, with an exercise price of $0.40 per share. These warrants are exercisable beginning on the date of issuance and will expire five years from the date of issuance. The gross proceeds from the offering were approximately $4.4 million, before deducting placement agent fees and other offering expenses. vTv intends to use the net proceeds for general corporate purposes, including working capital and research and development.

To delve deeper into vTv Therapeutics Inc., explore its history, mission, and operational framework, continue reading here: vTv Therapeutics Inc. (VTVT): History, Ownership, Mission, How It Works & Makes Money

vTv Therapeutics Inc. (VTVT) Mission Statement

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel, orally administered small molecule drug candidates. Specializing in addressing unmet medical needs, the company leverages cutting-edge technology to modulate human proteins and transform scientific innovation into safe and effective medicines.

At the heart of Company's mission is the optimization of human protein function to improve patient outcomes. The company's lead program, centered around cadisegliatin (also recognized as TTP399), is designed as an adjunct treatment specifically for type 1 diabetes.

vTv Therapeutics' mission is rooted in a commitment to developing treatments for chronic diseases, particularly type 1 diabetes, metabolic, and inflammatory disorders. Their approach involves creating innovative, orally administered small molecule drug candidates to address significant unmet medical needs.

More information about Company's history and background can be found here: vTv Therapeutics Inc. (VTVT): History, Ownership, Mission, How It Works & Makes Money

Vision

The vision of Company is to provide comprehensive healthcare services, integrate across national and international boundaries, and become a global healthcare organization, and be recognized as both a domestic and international healthcare and pharmaceutical company through innovation, quality, and competence.

Core Values

Company's core values include:

• Passion: A strong passion for science, particularly for research and development of drug therapies to treat metabolic and inflammatory disorders.
• Professionalism: Maintaining a high level of competence to deliver a return on investment to stakeholders, being flexible, innovative, and always seeking the best solutions, learning from mistakes, and showing respect to colleagues, collaborators, and vendor partners.
• Entrepreneurship: Being innovative and creative in finding solutions to develop the pipeline.
• Integrity: Integrity is the cornerstone of our business operations. We believe in doing things right and owning the results. We are committed to maintaining a culture of honesty, integrity, and accountability.

These values reflect a commitment to scientific excellence, ethical conduct, and a collaborative approach to drug development.

In 2024, vTv Therapeutics reported a cash position of $36.7 million as of December 31, compared to $9.4 million as of December 31, 2023. Research and Development expenses were $2.2 million for the three months ended December 31, 2024.

vTv Therapeutics Inc. (VTVT) Vision Statement of

As of April 2025, information on vTv Therapeutics Inc.'s (VTVT) specific vision statement is not readily available in the provided search results. Vision statements are typically future-oriented declarations that articulate the long-term goals and aspirations of a company. Without direct access to VTVT's official documents or recent statements, constructing a detailed analysis is challenging. However, based on the available information, we can infer aspects of their vision.

Given their focus on developing orally administered treatments for metabolic diseases, particularly type 1 diabetes, and inflammatory diseases, it's reasonable to assume that vTv Therapeutics envisions a future where:

• Patients have access to more convenient and effective treatments.
• The burden of managing chronic diseases is significantly reduced.
• Their innovative therapies play a key role in improving patient outcomes and quality of life.

To gain a comprehensive understanding of VTVT's vision statement, consulting their official website or investor relations materials is advisable. Further insights on vTv Therapeutics Inc. (VTVT) can be found here: vTv Therapeutics Inc. (VTVT): History, Ownership, Mission, How It Works & Makes Money

vTv Therapeutics Inc. (VTVT) Core Values of

While specific, publicly available details on vTv Therapeutics' mission statement, vision, and core values as of April 2025 are limited, we can infer their likely focus based on their activities, industry, and available information. vTv Therapeutics Inc. is a pharmaceutical company focused on developing orally administered treatments for metabolic diseases.

Based on the company's focus and publicly available information, here are potential core values with supporting evidence:

Innovation:

Innovation is likely a core value, considering their focus on developing novel therapies for metabolic diseases. Here's how they might demonstrate it:

• Research and Development: Investing significantly in R&D to discover and develop new drug candidates. For example, in 2023, vTv Therapeutics reported $7.6 million in research and development expenses.
• Novel Approaches: Focusing on unique mechanisms of action to address unmet needs in metabolic diseases.
• Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of their drug candidates.

Patient Focus:

A commitment to improving patient lives is a fundamental value for pharmaceutical companies. This is reflected in:

• Addressing Unmet Needs: Targeting diseases with significant unmet medical needs and limited treatment options.
• Improving Outcomes: Striving to develop therapies that improve patient outcomes and quality of life.
• Patient Safety: Prioritizing patient safety in all aspects of drug development and commercialization.

Integrity:

Operating with the highest ethical standards is crucial in the pharmaceutical industry. This includes:

• Regulatory Compliance: Adhering to all applicable laws and regulations governing drug development and commercialization.
• Transparency: Maintaining transparency in their interactions with stakeholders, including patients, healthcare professionals, and investors.
• Ethical Conduct: Upholding the highest ethical standards in all business practices.

Collaboration:

Working effectively with partners and stakeholders is essential for success in the pharmaceutical industry. Evidenced by:

• Strategic Partnerships: Collaborating with other companies, research institutions, and healthcare organizations to advance their programs.
• Open Communication: Fostering open communication and collaboration among employees, partners, and stakeholders.
• Teamwork: Encouraging teamwork and collaboration within the organization to achieve common goals.

Financial Responsibility:

Managing resources effectively is important for long-term sustainability. This can be seen through:

• Efficient Operations: Optimizing operational efficiency to minimize costs and maximize resources. The company's general and administrative expenses were $4.1 million for the year ended December 31, 2023.
• Strategic Investments: Making strategic investments in research and development and other initiatives to drive growth.
• Financial Discipline: Maintaining financial discipline and managing cash flow effectively. As of December 31, 2023, vTv Therapeutics had cash and cash equivalents of approximately $13.8 million

These inferred values are based on the available information and general expectations for pharmaceutical companies. For more insights, explore: Exploring vTv Therapeutics Inc. (VTVT) Investor Profile: Who’s Buying and Why?